Oxford Biomedica plc, a gene and cell therapy group, has signed a new three year Development & Supply Agreement (DSA) with Boehringer Ingelheim for the manufacture and supply of various types of viral vectors.   Under the terms of the DSA, Oxford Biomedica intends to manufacture GMP batches for Boehringer Ingelheim to support the development of viral vectors. The DSA also allows for the Group to manufacture and supply viral vector products in the future.   John Dawson, chief executive of...